Insider Buy/Sell Details for the Biotechnology Industry — Last 3 Months
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (3470)
Climb Bio, Inc. (CLYM)
Thomas Stephen Basil — Director
Shares
10,000
Price
$5.81
Total Value
$58.14K
Shares Held After
204,657
% of Holdings
4.7%
Roivant Sciences Ltd. (ROIV)
Gold Daniel Allen — Director
Shares
225,000
Price
$26.50
Total Value
$5.96M
Shares Held After
15,127,329
% of Holdings
1.5%
Roivant Sciences Ltd. (ROIV)
Gold Daniel Allen — Director
Shares
150,784
Price
$26.49
Total Value
$3.99M
Shares Held After
15,352,329
% of Holdings
1.0%
Roivant Sciences Ltd. (ROIV)
MANCHESTER KEITH S — Director
Shares
225,000
Price
$26.50
Total Value
$5.96M
Shares Held After
15,127,329
% of Holdings
1.5%
Roivant Sciences Ltd. (ROIV)
MANCHESTER KEITH S — Director
Shares
150,784
Price
$26.49
Total Value
$3.99M
Shares Held After
15,352,329
% of Holdings
1.0%
Roivant Sciences Ltd. (ROIV)
QVT Financial LP — Director by Deputization
Shares
225,000
Price
$26.50
Total Value
$5.96M
Shares Held After
15,127,329
% of Holdings
1.5%
Roivant Sciences Ltd. (ROIV)
QVT Financial LP — Director by Deputization
Shares
150,784
Price
$26.49
Total Value
$3.99M
Shares Held After
15,352,329
% of Holdings
1.0%
Mineralys Therapeutics, Inc. (MLYS)
Rodman David Malcom — Chief Medical Officer
Shares
6,348
Price
$27.58
Total Value
$175.10K
Shares Held After
44,089
% of Holdings
12.6%
Mineralys Therapeutics, Inc. (MLYS)
Rodman David Malcom — Chief Medical Officer
Shares
4,166
Price
$27.33
Total Value
$113.86K
Shares Held After
50,437
% of Holdings
7.6%
Mineralys Therapeutics, Inc. (MLYS)
Rodman David Malcom — Chief Medical Officer
Shares
3,541
Price
$27.33
Total Value
$96.78K
Shares Held After
50,437
% of Holdings
6.6%
IONIS PHARMACEUTICALS INC (IONS)
Swayze Eric — EVP Research
Shares
6,207
Price
$82.07
Total Value
$509.40K
Shares Held After
32,105
% of Holdings
16.2%
IONIS PHARMACEUTICALS INC (IONS)
Swayze Eric — EVP Research
Shares
9,435
Price
$81.56
Total Value
$769.51K
Shares Held After
38,312
% of Holdings
19.8%
Zenas BioPharma, Inc. (ZBIO)
Allen Patricia L — Director
Shares
4,160
Price
$26.36
Total Value
$109.66K
Shares Held After
19,860
% of Holdings
20.9%
OCULAR THERAPEUTIX, INC (OCUL)
Nayak Sanjay — Chief Strategy Officer
Shares
10,348
Price
$9.04
Total Value
$93.55K
Shares Held After
332,412
% of Holdings
3.0%
OCULAR THERAPEUTIX, INC (OCUL)
Dugel Pravin — Director
Shares
124,882
Price
$9.04
Total Value
$1.13M
Shares Held After
3,033,078
% of Holdings
4.0%
OCULAR THERAPEUTIX, INC (OCUL)
Notman Donald — Chief Operating Officer
Shares
11,446
Price
$9.04
Total Value
$103.47K
Shares Held After
366,356
% of Holdings
3.0%
OCULAR THERAPEUTIX, INC (OCUL)
Waheed Nadia — Chief Medical Officer
Shares
7,863
Price
$9.04
Total Value
$71.08K
Shares Held After
318,417
% of Holdings
2.4%
Climb Bio, Inc. (CLYM)
Thomas Stephen Basil — Director
Shares
90,000
Price
$5.23
Total Value
$470.99K
Shares Held After
214,657
% of Holdings
29.5%
Entera Bio Ltd. (ENTX)
Rubin Steven D — Director
Shares
5,000
Price
$1.49
Total Value
$7.45K
Shares Held After
15,000
% of Holdings
33.3%
Zivo Bioscience, Inc. (ZIVO)
STROME MARK E — 10% Owner
Shares
20,000
Price
$9.77
Total Value
$195.40K
Shares Held After
472,942
% of Holdings
4.2%
Roivant Sciences Ltd. (ROIV)
Gold Daniel Allen — Director
Shares
275,000
Price
$26.76
Total Value
$7.36M
Shares Held After
15,503,113
% of Holdings
1.7%
Roivant Sciences Ltd. (ROIV)
Gold Daniel Allen — Director
Shares
150,000
Price
$26.72
Total Value
$4.01M
Shares Held After
15,778,113
% of Holdings
0.9%
Roivant Sciences Ltd. (ROIV)
MANCHESTER KEITH S — Director
Shares
275,000
Price
$26.76
Total Value
$7.36M
Shares Held After
15,503,113
% of Holdings
1.7%
Roivant Sciences Ltd. (ROIV)
MANCHESTER KEITH S — Director
Shares
150,000
Price
$26.72
Total Value
$4.01M
Shares Held After
15,778,113
% of Holdings
0.9%
Roivant Sciences Ltd. (ROIV)
QVT Financial LP — Director by Deputization
Shares
275,000
Price
$26.76
Total Value
$7.36M
Shares Held After
15,503,113
% of Holdings
1.7%
Roivant Sciences Ltd. (ROIV)
QVT Financial LP — Director by Deputization
Shares
150,000
Price
$26.72
Total Value
$4.01M
Shares Held After
15,778,113
% of Holdings
0.9%
Palisade Bio, Inc. (PALI)
Finley John David — Director
Shares
3,896
Price
$1.75
Total Value
$6.82K
Shares Held After
27,353
% of Holdings
12.5%
Palisade Bio, Inc. (PALI)
Jones Mitchell Lawrence — Chief Medical Officer
Shares
1,989
Price
$1.75
Total Value
$3.48K
Shares Held After
13,263
% of Holdings
13.0%
Mineralys Therapeutics, Inc. (MLYS)
Rodman David Malcom — Chief Medical Officer
Shares
521
Price
$29.64
Total Value
$15.44K
Shares Held After
50,437
% of Holdings
1.0%
Mineralys Therapeutics, Inc. (MLYS)
Rodman David Malcom — Chief Medical Officer
Shares
5,828
Price
$28.94
Total Value
$168.63K
Shares Held After
50,958
% of Holdings
10.3%
Zenas BioPharma, Inc. (ZBIO)
Allen Patricia L — Director
Shares
5,000
Price
$26.50
Total Value
$132.50K
Shares Held After
15,700
% of Holdings
31.8%
Zenas BioPharma, Inc. (ZBIO)
Allen Patricia L — Director
Shares
5,700
Price
$24.34
Total Value
$138.74K
Shares Held After
10,700
% of Holdings
53.3%
Zenas BioPharma, Inc. (ZBIO)
Allen Patricia L — Director
Shares
5,000
Price
$23.77
Total Value
$118.85K
Shares Held After
5,000
% of Holdings
100.0%
Tyra Biosciences, Inc. (TYRA)
Bensen Daniel — Chief Discovery Officer
Shares
5,872
Price
$33.37
Total Value
$195.93K
Shares Held After
146,981
% of Holdings
3.8%
Tyra Biosciences, Inc. (TYRA)
Bensen Daniel — Chief Discovery Officer
Shares
2,128
Price
$31.50
Total Value
$67.04K
Shares Held After
152,853
% of Holdings
1.4%
Neuraxis, INC (NRXS)
Hannasch Brian — 10% Owner
Shares
40,000
Price
$4.92
Total Value
$196.80K
Shares Held After
1,211,522
% of Holdings
3.3%
KalVista Pharmaceuticals, Inc. (KALV)
Palleiko Benjamin L — Director
Shares
3,354
Price
$15.70
Total Value
$52.66K
Shares Held After
428,286
% of Holdings
0.8%
Surrozen, Inc./DE (SRZN)
TCG Crossover GP II, LLC — 10% Owner
Shares
546
Price
$23.86
Total Value
$13.03K
Shares Held After
651,112
% of Holdings
0.1%
Surrozen, Inc./DE (SRZN)
TCG Crossover GP II, LLC — 10% Owner
Shares
547
Price
$23.86
Total Value
$13.05K
Shares Held After
651,114
% of Holdings
0.1%
ONCOLYTICS BIOTECH INC (ONCY)
Andrews Patricia S — Director
Shares
35,400
Price
$0.86
Total Value
$30.29K
Shares Held After
78,128
% of Holdings
45.3%
ONCOLYTICS BIOTECH INC (ONCY)
Hagerman Allison — VP, Product Development
Shares
10,000
Price
$0.83
Total Value
$8.30K
Shares Held After
115,059
% of Holdings
8.7%
ONCOLYTICS BIOTECH INC (ONCY)
Seizinger Bernd R. — Director
Shares
40,000
Price
$0.85
Total Value
$33.86K
Shares Held After
566,991
% of Holdings
7.1%
ONCOLYTICS BIOTECH INC (ONCY)
Look Kirk — Chief Financial Officer
Shares
12,000
Price
$0.84
Total Value
$10.10K
Shares Held After
287,515
% of Holdings
4.2%
ONCOLYTICS BIOTECH INC (ONCY)
Heineman Thomas Charles — Chief Medical Officer
Shares
12,132
Price
$0.83
Total Value
$10.03K
Shares Held After
282,818
% of Holdings
4.3%
ONCOLYTICS BIOTECH INC (ONCY)
Brown Deborah Margaret — Director
Shares
25,000
Price
$0.85
Total Value
$21.24K
Shares Held After
109,851
% of Holdings
22.8%
ONCOLYTICS BIOTECH INC (ONCY)
Pisano Wayne — Director
Shares
30,000
Price
$0.84
Total Value
$25.34K
Shares Held After
492,414
% of Holdings
6.1%
ONCOLYTICS BIOTECH INC (ONCY)
Kelly Jared — Director
Shares
29,500
Price
$0.84
Total Value
$24.84K
Shares Held After
109,000
% of Holdings
27.1%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Smith Hunter C — Chief Financial Officer
Shares
100
Price
$100.10
Total Value
$10.01K
Shares Held After
118,466
% of Holdings
0.1%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Smith Hunter C — Chief Financial Officer
Shares
800
Price
$98.99
Total Value
$79.19K
Shares Held After
118,566
% of Holdings
0.7%
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Smith Hunter C — Chief Financial Officer
Shares
400
Price
$97.67
Total Value
$39.07K
Shares Held After
119,366
% of Holdings
0.3%
Showing 1851–1900 of 3470 transactions (page 38 of 70)